Financial Performance - The company reported a negative retained earnings balance, leading to no cash dividends or stock bonuses for the year[5]. - The company has not achieved profitability since its listing[3]. - The company's operating revenue for 2022 was ¥354.87 million, an increase of 15.10% compared to ¥308.30 million in 2021[24]. - The net profit attributable to shareholders for 2022 was ¥35.82 million, a decrease of 54.81% from ¥79.27 million in 2021[24]. - The net profit after deducting non-recurring gains and losses was ¥16.35 million, down 71.53% from ¥57.44 million in 2021[24]. - The net cash flow from operating activities was ¥61.13 million, a decrease of 12.87% compared to ¥70.16 million in 2021[24]. - The company's total assets at the end of 2022 were ¥2.03 billion, an increase of 41.65% from ¥1.43 billion at the end of 2021[24]. - The net assets attributable to shareholders increased by 178.55% to ¥1.58 billion at the end of 2022 from ¥565.68 million at the end of 2021[24]. - The basic earnings per share for 2022 were ¥0.29, a decrease of 57.97% from ¥0.69 in 2021[25]. - The company reported a credit impairment loss of 25.30 million yuan for accounts receivable, indicating potential risks associated with bad debts as the scale of accounts receivable increases[119]. Governance and Compliance - A standard unqualified audit report was issued by the accounting firm, indicating the financial statements are accurate and complete[4]. - The company has no special governance arrangements or significant matters affecting governance[8]. - The board of directors and supervisory board members all attended the board meeting, ensuring proper governance[4]. - The company has not disclosed any violations of decision-making procedures for external guarantees[7]. - The company has established a clear cash dividend policy in accordance with relevant regulations, ensuring the protection of minority shareholders' rights[197]. - The governance structure includes the shareholders' meeting, board of directors, supervisory board, and senior management, ensuring comprehensive oversight[200]. - The company has not proposed any cash profit distribution plan during the reporting period despite having positive distributable profits[198]. - The decision-making procedures and mechanisms for the cash dividend policy are complete and transparent, allowing for adequate expression of opinions by minority shareholders[198]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 21.34% in 2022 from 16.78% in 2021, reflecting a growth of 4.56 percentage points[25]. - The company increased its R&D investment by 46.36% year-on-year to maintain product competitiveness[37]. - R&D expenditure reached 75.72 million yuan, a year-on-year increase of 46.36%, accounting for 21.34% of operating revenue[39]. - The company has developed 13 standardized models in the field of integrated communication, becoming a leading enterprise in this sector after over ten years of innovation[82]. - The company has a high proportion of technical personnel, with 43.2% of its workforce in R&D roles, which is critical for ongoing innovation[112]. - The company has undertaken multiple military projects, including 37 finalized products and 25 ongoing research projects, ensuring its technological edge[104]. - The company has established a mature R&D system and a dedicated product strategy planning team to analyze customer needs and industry trends[104]. Market and Business Strategy - The company plans to expand into the power industry specialized network market, aiming to create a fourth business segment[38]. - The company is actively expanding into the civil market, targeting the power industry with products based on domestic technology and information security[42]. - The company is focusing on the integration of communication, ship communication, and information security as its three core business segments, aligning with national defense information construction needs[81]. - The company is exploring opportunities in other related fields while focusing on the electric power industry[163]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of the fiscal year[176]. Risks and Challenges - The company faces various operational risks, which are detailed in the management discussion and analysis section of the report[3]. - The company faces risks related to the decline in the delivery quantity of ship communication products, which are a major source of revenue, if the construction and upgrade frequency of target ships decreases[115]. - The company has a significant reliance on military communication products, and any adverse changes in the defense budget or procurement policies could negatively impact operational performance[114]. - The company is exposed to risks related to the promotion of integrated communication products in military applications, which may not meet expectations due to various uncertainties[115]. - The company faces risks related to rapid technological updates and the need for new product development to maintain competitiveness in the military communication sector[111]. Employee and Management Structure - The company has a total of 375 employees, with 224 in the parent company and 151 in major subsidiaries[193]. - The employee composition includes 59 production personnel, 58 sales personnel, 162 technical personnel, 18 financial personnel, and 78 administrative personnel[193]. - The company has established a salary policy that aligns with its overall development strategy, ensuring that compensation supports strategic goals and motivates employees[194]. - The remuneration structure includes a basic annual salary and a performance-based annual salary, with the latter linked to the company's operational performance[182]. - Changes in personnel included the election of Wu Shinjun as an independent director and the appointment of Zhao Jiarui as the secretary of the board[183]. Financial Management - The company reported a significant increase in financial expenses, up 148.99% to CNY 23,567,087.19, due to the cessation of capitalizing interest expenses[129]. - The company’s gross margin is influenced by various factors, and any increase in competition or costs could lead to a decline in gross margin, impacting overall performance[119]. - The company has implemented an IPD R&D management process to drive product innovation and provide comprehensive information security solutions for clients[162]. - The company aims to enhance its R&D investment in new products and technologies, focusing on military and civil communication solutions[157]. Future Outlook - The management provided guidance for the upcoming quarter, projecting continued revenue growth and improved profitability metrics[173]. - The company reported a significant increase in revenue, achieving a total of $1.5 billion for the quarter, representing a 20% year-over-year growth[176]. - New product launches included a cutting-edge software solution that is projected to generate an additional $200 million in revenue over the next year[176]. - Future outlook includes plans for market expansion and potential mergers and acquisitions to enhance growth strategies[173].

Financial Performance - The company reported significant revenue fluctuations due to high reliance on military business, which is influenced by various factors including user demand and procurement plans [3]. - The company's operating revenue for the first half of the year was ¥69,430,522.02, a decrease of 63.76% compared to ¥191,567,254.97 in the same period last year [19]. - The total profit for the reporting period was -¥58,974,827.08, representing a decline of 224.51% from ¥47,365,269.75 in the previous year [19]. - The net profit attributable to shareholders was -¥59,673,824.05, down 260.82% from ¥37,106,455.42 year-on-year [19]. - The net cash flow from operating activities decreased by 3,503.21%, amounting to -¥72,827,745.22 compared to ¥2,139,969.97 in the previous year [19]. - The company achieved revenue of 69.43 million yuan, a year-on-year decrease of 63.76%, with a net profit attributable to shareholders of -59.67 million yuan, a year-on-year decrease of 260.82% [80]. - In Q2, the company realized revenue of 41.72 million yuan, a quarter-on-quarter increase of 50.60% [80]. - The gross margin in Q2 increased by 13.06 percentage points quarter-on-quarter [80]. Risks and Challenges - The company has outlined potential risks in its operations, including project delays and significant changes in demand, which could lead to increased profit volatility or even losses [3]. - The report includes a forward-looking statement risk declaration, indicating that future plans and strategies do not constitute a commitment to investors [5]. - The company faces risks related to revenue volatility due to high dependence on military contracts and the influence of external factors such as procurement plans and geopolitical conditions [110]. - The company’s gross profit margin may decline due to increased competition, rising costs of raw materials, and changes in project implementation methods, which could adversely affect operating performance [116]. - The company recognized a credit impairment loss of 14.42 million yuan for accounts receivable during the reporting period, indicating potential risks related to bad debts as the scale of accounts receivable continues to grow [116]. Research and Development - Research and development expenses reached ¥38,937,200, accounting for 56.08% of operating revenue, an increase of 38.97 percentage points year-on-year [20][21]. - R&D expenses totaled approximately ¥38.94 million, an increase of 18.81% compared to ¥32.77 million in the same period last year [102]. - The company has a total of 182 R&D personnel, accounting for 40% of the total workforce, with R&D investment amounting to 38.94 million yuan, representing 56.08% of revenue [90]. - The company has filed a total of 32 patents for its cloud PC product, including 23 invention patents, enhancing its competitive edge [83]. - The company has developed advanced audio and video processing technology that ensures video transmission quality even under poor network conditions, maintaining clarity and smoothness despite delays and packet loss [62]. Product Development and Strategy - The company continues to implement a strategy of balanced development between military and civilian products, focusing on AI technology as a core driver [28]. - The company is transitioning from a traditional military information enterprise to a "cloud computing + AI solution provider," with a business layout of two divisions and two product lines [28]. - The cloud PC product line aims to capture the commercial computer market, providing a new category of computing products to meet user needs for secure and efficient multi-network and mobile office solutions [28]. - The AI Agent product line features the self-developed NuwaAI model, which offers digital human products to enhance user productivity and support personal digital creation [32]. - The company has established a complete digital infrastructure product ecosystem driven by AI, covering computing, storage, application, and security [34]. Governance and Compliance - The board of directors confirmed the authenticity and completeness of the financial report for the first half of 2025, which has not been audited [4]. - There are no plans for profit distribution or capital reserve conversion during this reporting period [5]. - The company has not experienced any non-operational fund occupation by controlling shareholders or related parties [6]. - The company has not violated decision-making procedures regarding external guarantees [7]. - The company has not disclosed any special governance arrangements or significant matters during this reporting period [5]. Market Outlook - The military informationization market in China is projected to grow from 1,643.21 billion RMB in 2023 to approximately 2,000 billion RMB by 2025, driven by increasing defense spending [57]. - The information security market in China is projected to grow from 130.77 billion CNY in 2019 to 229.01 billion CNY by 2024, with a compound annual growth rate (CAGR) of 11.90% [63]. - The global AI Agent market is projected to grow from approximately $5 billion in 2024 to over $30 billion by 2030, with a compound annual growth rate of about 35%-40% [76]. Shareholder Information - The company held its first extraordinary shareholders' meeting on May 16, 2025, electing a new board of directors for a term of three years [131]. - The company did not propose any profit distribution or capital reserve transfer plans for the half-year period, with no dividends or stock bonuses declared [132]. - The company has a total of 30,962,974 restricted shares held by Zhu Guosheng, which will be tradable starting from March 23, 2026 [191]. - The total number of common shareholders as of the end of the reporting period is 8,313 [186]. - The largest shareholder, Zhu Guosheng, holds 30,962,974 shares, representing 20.34% of the total shares [188].

Financial Performance - The company's operating revenue for Q3 2023 was ¥42,470,718.02, representing a decrease of 21.02% compared to the same period last year[6]. - The net profit attributable to shareholders for the year-to-date period was ¥19,485,755.46, down 10.81% year-on-year[6]. - Total operating revenue for the first three quarters of 2023 was CNY 163,303,207.20, a decrease of 10.8% compared to CNY 183,095,707.29 in the same period of 2022[24]. - The net profit for the first three quarters of 2023 was CNY 19,158,240.94, compared to a net loss of CNY 21,620,226.43 in the same period of 2022[25]. - The company reported a basic and diluted earnings per share of CNY 0.13 for the first three quarters of 2023, recovering from a loss of CNY 0.18 per share in 2022[25]. Research and Development - Research and development expenses totaled ¥23,163,155.22 in Q3 2023, accounting for 54.54% of operating revenue, an increase of 19.32 percentage points year-on-year[7]. - Research and development expenses for the first three quarters of 2023 were CNY 57,734,926.45, slightly increasing from CNY 56,829,844.83 in 2022, indicating continued investment in innovation[24]. - The company is actively engaged in research and development, with orderly progress in production and sales[18]. Assets and Liabilities - The total assets as of the end of the reporting period were ¥1,927,843,895.26, a decrease of 4.92% from the end of the previous year[7]. - The total assets as of the end of the reporting period were CNY 1,927,843,895.26, a decrease from CNY 2,027,616,605.83 at the end of the previous period[22]. - Total liabilities decreased to CNY 328,094,730.64 from CNY 448,810,286.83, indicating a reduction of 26.9%[22]. - The company has reduced short-term borrowings to CNY 69,180,000.00 from CNY 126,900,000.00, reflecting a strategic effort to manage debt levels[22]. Cash Flow - The cash flow from operating activities for the year-to-date period was negative at -¥8,092,431.15, indicating increased payments to suppliers[7]. - The company's cash flow from operating activities for the first three quarters of 2023 showed significant improvement, contributing positively to the overall financial health[26]. - Cash inflow from operating activities for the first three quarters of 2023 reached approximately CNY 270.75 million, a 39.7% increase from CNY 193.86 million in the same period of 2022[27]. - Net cash flow from operating activities was negative CNY 8.09 million, worsening from negative CNY 4.59 million year-over-year[27]. - Cash inflow from investment activities totaled CNY 241.30 million, with a significant cash outflow of CNY 515.15 million, resulting in a net cash flow of negative CNY 273.85 million[27]. - Cash inflow from financing activities was CNY 69.18 million, a sharp decline from CNY 1.20 billion in the previous year, leading to a net cash flow of negative CNY 80.37 million[28]. Shareholder Information - The top shareholder, Zhu Guosheng, holds 25.14% of the shares, with a total of 38,269,774 shares[15]. - The second-largest shareholder, Jinpai Co., Ltd., owns 15.37% of the shares, totaling 23,400,000 shares[15]. - The company has a total of 6,325,661 shares held by Shenzhen Zhongyan Innovation Investment Partnership, accounting for 4.16% of the shares[15]. - The company has a total of 9,082 common shares outstanding at the end of the reporting period[15]. Government Support - The company received government subsidies amounting to ¥1,631,902.45 during the reporting period, closely related to its normal business operations[9]. Accounting and Reporting Changes - The company has implemented new accounting standards starting from 2023, which may affect the financial reporting[30].

Profit Distribution - The profit distribution plan for 2025 proposes a cash dividend of 8.8 RMB per 10 shares, totaling approximately 559.34 million RMB, which accounts for 61.69% of the net profit attributable to the parent company [22]. - The total cash dividend for 2025, including the interim distribution of 317.50 million RMB, amounts to approximately 876.84 million RMB, representing 96.71% of the net profit attributable to the parent company [22]. - The company completed the semi-annual profit distribution in October 2025, amounting to 317.50 million RMB [22]. - The profit distribution plan has been approved by the board and is pending shareholder approval [22]. - The company has implemented a stable cash dividend policy, distributing approximately 70% of cumulative net profit to shareholders since its listing [194]. - The cash dividend for the current period is set at CNY 876,837,705.32, which represents 96.71% of the net profit attributable to ordinary shareholders [197]. - Over the last three accounting years, the total cash dividend amount (including tax) reached CNY 2,454,100,137.72, with an average annual net profit of CNY 804,514,989.66, resulting in a cash dividend ratio of 305.04% [199]. - The company plans to maintain a cash dividend frequency of twice a year during the "14th Five-Year Plan" period [194]. - The cash dividend policy aligns with the company's articles of association and has been approved by the shareholders' meeting [195]. - There were no shares issued as stock dividends or increases in capital reserves during the current reporting period [197]. - The company has not proposed a cash profit distribution plan despite having positive distributable profits [196]. - The net profit attributable to ordinary shareholders for the most recent accounting year was CNY 906,685,963.56 [199]. - The retained earnings at the end of the most recent accounting year amounted to CNY 2,475,188,485.11 [199]. - The company has not repurchased or canceled any shares in the last three accounting years [199]. - The company approved the repurchase and cancellation of 149,602 restricted shares, with a total repurchase amount of 463,738.88 yuan [200]. - On May 21, 2025, the company completed the cancellation of 149,602 restricted shares [200]. - The company agreed to unlock 139,938 restricted shares for eligible incentive objects as the conditions for the second unlock period were met [200]. - A total of 139,938 shares from the equity incentive plan were listed for circulation on May 30, 2025 [200]. - The company granted 6.217 million restricted shares to 168 eligible incentive objects at a price of 13.70 yuan per share on May 16, 2025 [200]. - The actual number of restricted shares granted in the second phase of the incentive plan was 612.8 thousand shares, with 165 individuals receiving the grants [200]. Financial Performance - The company's operating revenue for 2025 was approximately CNY 4.22 billion, a decrease of 4.87% compared to 2024 [42]. - The total profit for 2025 reached approximately CNY 1.21 billion, reflecting an increase of 18.24% year-over-year [42]. - The net profit attributable to shareholders for 2025 was approximately CNY 906.69 million, up 15.03% from 2024 [42]. - The basic earnings per share for 2025 was CNY 1.43, representing a 14.40% increase compared to 2024 [41]. - The net cash flow from operating activities for 2025 was approximately CNY 970.87 million, an increase of 23.48% year-over-year [42]. - The company's total assets as of the end of 2025 were approximately CNY 6.88 billion, a 5.73% increase from the end of 2024 [42]. - The weighted average return on equity for 2025 was 22.75%, an increase of 3.17 percentage points compared to 2024 [43]. - The net profit after deducting non-recurring gains for 2025 was approximately CNY 833.26 million, an increase of 11.22% from 2024 [42]. - The company reported non-recurring gains totaling approximately CNY 73.42 million for 2025, compared to CNY 39.02 million in 2024 [46]. - The company achieved a net profit attributable to shareholders of 907 million yuan, an increase of 118.49 million yuan, representing a year-on-year growth of 15.03% [59]. - The gross profit margin for the main business was 65.50%, an increase of 1.53 percentage points compared to the same period last year [87]. - The company reported a 23.48% increase in cash flow from operating activities, amounting to CNY 970.87 million [85]. - The company’s financial performance was supported by a significant increase in other income, which rose by 59.84% to CNY 104.50 million [86]. Operational Stability and Risks - The company has no unabsorbed losses that would affect dividend distribution [23]. - There are no significant risks that materially impact the company's operations during the reporting period [25]. - The company received a standard unqualified audit report from KPMG Huazhen [21]. - The board of directors and senior management guarantee the authenticity and completeness of the annual report [19]. - The company has no non-operating fund occupation by controlling shareholders or related parties [24]. - There are no violations of decision-making procedures regarding external guarantees [25]. Market and Product Development - The company’s main business remains stable, focusing on over-the-counter drugs, prescription drugs, and health consumer products across various fields [54]. - The company is expanding its sales channels, including traditional and online platforms, with a focus on e-commerce sites like Tmall and JD.com [58]. - The company emphasizes a lean production model and quality control throughout the entire product lifecycle, ensuring safety and compliance with regulations [58]. - The company’s product portfolio includes key items such as probiotics, health supplements, and traditional Chinese medicine, targeting various health issues [54][55]. - The company is actively pursuing market expansion through both online and offline channels, including partnerships with local life service platforms [58]. - The company has implemented strategic procurement and production practices to enhance efficiency and reduce costs [58]. - The OTC business revenue was 2.992 billion yuan, down 8.39% year-on-year due to changes in terminal demand and industry channel structure adjustments [70]. - The health consumer goods segment reported revenue of 494 million, a year-on-year increase of 43.19% [72]. - The prescription drug segment's revenue was 720 million, reflecting a year-on-year decline of 9.15% due to structural adjustments and underperformance of potential products [73]. - The company completed the acquisition of Jingcheng Huyao, enhancing its product matrix with advantageous products like Liuwei Dihuang Oral Liquid and Nao Li Jing Syrup [71]. - The company is focusing on enhancing brand image and market penetration for its "P9 Probiotic" and "Gan Chun Pian" products, targeting differentiated consumer needs [72]. - The company is focusing on the integration of traditional Chinese medicine in health management, promoting preventive care and rehabilitation services [114]. - The company aims to develop a comprehensive product ecosystem from disease treatment to health management, focusing on traditional Chinese medicine and modern health products [153]. Research and Development - The company’s R&D investment intensity exceeded 5%, with over 300 patents authorized and participation in the formulation of 2 national standards [68]. - The company aims for a research and development investment intensity of 5.19% by 2025, an increase of 0.37 percentage points year-on-year [75]. - The company submitted 92 patent applications and was granted 61 patents during the reporting period, strengthening its intellectual property portfolio [76]. - The company achieved a strategic upgrade in digitalization and smart manufacturing, implementing MES systems for automated management of production processes [77]. - The company is focusing on innovation in drug development, particularly in traditional Chinese medicine, to enhance its product matrix and R&D capabilities [164]. - The company is committed to increasing R&D investment, focusing on clinical value and real-world research, with a goal of transforming R&D outcomes into new growth engines [148]. - The company is advancing 20 new drug development projects across various key areas, including traditional Chinese medicine and biopharmaceuticals [122]. - Research and development expenses increased by 17.14% to CNY 152.79 million, reflecting the company's commitment to innovation [85]. - Total R&D investment for the period reached 21,914.86 million RMB, accounting for 5.19% of the company's operating revenue [104]. - The number of R&D personnel is 507, representing 11.65% of the total workforce [102]. - The age structure of R&D personnel shows that 41.2% are under 30 years old, while 38.3% are between 30-40 years old [103]. Governance and Management - The company has undergone changes in its subsidiary structure, including the acquisition of Anhui Jingcheng Huyao Pharmaceutical Co., which is expected to have a minor impact on overall performance [143]. - The company has restructured its governance by increasing the board size to 11 members and adding independent and employee representative directors to improve decision-making and oversight [167]. - The company reported a total shareholding increase of 643,600 shares, rising from 1,024,000 to 1,667,600 shares during the reporting period, representing a 62.8% increase [169]. - The total pre-tax compensation for executives reached 292.89 million yuan, with significant increases in individual compensation for key personnel [170]. - The chairman, Liu Weiquan, increased his shareholding by 119,000 shares, bringing his total to 338,000 shares, reflecting a 54.3% increase [169]. - The new board member, Bai Xiaosong, has not yet acquired shares, indicating a potential future investment [169]. - The company has implemented measures to ensure the independence of its operations from its controlling shareholders, including commitments to resolve industry competition issues [168]. - The company plans to expand its market presence and enhance product development strategies, although specific figures were not disclosed [168]. - The total number of shares held by the general manager, Xu Yongqian, increased by 101,000 shares, totaling 170,666 shares, marking a 145% increase [169]. - The company has appointed new independent directors, enhancing governance and oversight capabilities [170]. - The financial director, Huang Yanwei, has been granted 80,000 shares as part of an incentive plan, indicating a focus on aligning management interests with shareholder value [170]. - The company’s remuneration and assessment committee has undergone changes, with new members being appointed effective December 29, 2025 [181]. - The company’s board of directors has established specialized committees, including an audit committee and a remuneration and assessment committee [181]. - The company’s performance evaluation criteria are deemed objective and fair, accurately reflecting the work of the assessed individuals [176]. - No instances of salary withholding or recovery were reported during the reporting period [176]. - The company’s board members participated in all scheduled meetings, with no instances of absenteeism reported for the majority of members [180]. Employee and Talent Management - The total number of employees in the parent company is 1,511, while the total number of employees in major subsidiaries is 2,841, resulting in a combined total of 4,352 employees [189]. - The company has 872 retired employees for whom it bears expenses [189]. - The professional composition includes 1,332 production personnel, 1,376 sales personnel, and 1,196 technical personnel [189]. - The company has a total of 357 employees with a master's degree or higher, 1,429 with a bachelor's degree, and 1,108 with a college diploma [190]. - The total hours of outsourced labor amounted to 190,258.5 hours, with total payments for outsourced labor reaching ¥5,995,745.08 [193]. - The company emphasizes a performance-based compensation policy, linking salary growth to economic benefits and productivity improvements [191]. - The company is implementing a talent development plan to support high-quality development, focusing on various training programs for different employee levels [192]. - The company held multiple meetings to discuss the appointment of key management positions, including the financial director and general manager [184][185]. Strategic Initiatives and Future Outlook - The company is focused on expanding its health consumer products, particularly in areas such as nutrition and gastrointestinal health, while exploring new product opportunities [151]. - The company is committed to a long-term strategy of brand and innovation-driven growth, aiming to become a trusted and respected enterprise in the traditional Chinese medicine industry [149]. - The company aims to enhance organizational efficiency and talent competitiveness through strategic leadership and collaborative mechanisms [156]. - In 2025, the company anticipates challenges from national policies on centralized drug procurement, which may pressure prices and market share for certain products [158]. - The company plans to optimize its competitive strategies and enhance market penetration in response to price pressures from centralized procurement policies [158]. - The implementation of drug price governance and tax policy adjustments in 2025 may increase the company's tax burden and require a focus on fair pricing practices [159]. - The company is actively monitoring raw material prices and supply risks, with strategic reserves in place for key medicinal materials to mitigate cost fluctuations [163]. - The company is set to deepen its digital and intelligent integration, aiming to create a smart operational ecosystem that enhances production efficiency and quality control through AI and big data technologies [155]. - The company plans to optimize its industrial ecosystem and improve its supply chain layout through strategic investments and acquisitions in key areas such as traditional Chinese medicine and specialized medical foods [152]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential deals [171]. - A new marketing strategy has been implemented, focusing on digital channels, which is expected to increase customer engagement by 30% [171]. - The management team emphasized the importance of sustainability initiatives, aiming for a 25% reduction in carbon footprint by 2025 [171].

福建海通发展股份有限公司2025 年年度报告 公司代码：603162 公司简称：海通发展 福建海通发展股份有限公司 2025 年年度报告 1 / 252 福建海通发展股份有限公司2025 年年度报告 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司全体董事出席董事会会议。 三、 致同会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、公司负责人曾而斌、主管会计工作负责人刘国勇及会计机构负责人（会计主管人员）乐君杰 声明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司拟向全体股东每10股派发现金红利0.50元（含税）。截至2026年3月3日，公司总股本 927,946,308股，以扣除不参与利润分配的拟回购注销的限制性股票302,000股后的927,644,308股为 基数计算，合计拟派发现金红利46,382,215.40元（含税）。 公司拟以资本公积转增股本方式向全体股东每10股转增4.80股。截至2026 ...

中稀有色金属股份有限公司2025 年年度报告 重要提示 公司代码：600259 公司简称：中稀有色 中稀有色金属股份有限公司 2025 年年度报告 1 / 287 中稀有色金属股份有限公司2025 年年度报告 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司全体董事出席董事会会议。 三、大华会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、公司负责人杨杰、主管会计工作负责人陈志新 及会计机构负责人（会计主管人员）王庆翔 声明：保证年度报告中财务报告的真实、准确、完整。 本年度报告内容涉及的未来计划、发展战略等前瞻性陈述，因存在不确定性，不构成公司对 投资者的实质承诺，请投资者注意投资风险。 五、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经大华会计师事务所（特殊普通合伙）审计，公司2025年度母公司实现净利润85,304,136.22 元，提取法定盈余公积8,530,413.62元，加上年初未分配利润0元，截至本报告期末，母公司实际 可供分配利润76,773,722 ...

晋亿实业股份有限公司2025 年年度报告 公司代码：601002 公司简称：晋亿实业 晋亿实业股份有限公司 2025 年年度报告 1 / 203 晋亿实业股份有限公司2025 年年度报告 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司全体董事出席董事会会议。 三、天健会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、公司负责人蔡永龙、主管会计工作负责人王伟及会计机构负责人（会计主管人员）王伟声明： 保证年度报告中财务报告的真实、准确、完整。 五、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经董事会决议，公司 2025 年度拟以实施权益分派股权登记日登记的总股本为基数分配利润。 公司拟向全体股东每 10 股派发现金红利 0.8 元（含税）。截至 2025 年 12 月 31 日，公司总股本 954,440,720 股，以此计算合并拟派发现金红利 76,355,257.60 元（含税）。如在本公告披露之 日起至实施权益分派股权登记日期间，公司总股本发生变动的 ...

江苏新泉汽车饰件股份有限公司2025 年年度报告 公司代码：603179 公司简称：新泉股份 江苏新泉汽车饰件股份有限公司 2025 年年度报告 1 / 219 江苏新泉汽车饰件股份有限公司2025 年年度报告 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司全体董事出席董事会会议。 三、 立信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、公司负责人唐志华、主管会计工作负责人李新芳及会计机构负责人（会计主管人员）宋燕青 声明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 2026年3月19日，公司召开第五届董事会第十五次会议，审议通过了公司2025年度利润分配预 案。公司2025年度利润分配预案为：拟以实施权益分派股权登记日的总股本为基数，向全体股东 每10股派发现金股利3.00元（含税），剩余未分配利润结转以后年度，以资本公积金转增股本， 每10股转增4股，不送红股。截至2025年12月31日公司总股本 ...

安徽皖维高新材料股份有限公司2025 年年度报告 公司代码：600063 公司简称：皖维高新 安徽皖维高新材料股份有限公司 2025 年年度报告 1/213 安徽皖维高新材料股份有限公司2025 年年度报告 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司全体董事出席董事会会议。 三、 天健会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、公司负责人吴福胜、主管会计工作负责人孙先武及会计机构负责人（会计主管人员）黄敬 声明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经天健会计师事务所（特殊普通合伙）年审注册会计师张扬、张运楼审计，并出具标准无保 留意见的审计报告。以合并报表口径计算，公司2025年度归属于母公司股东的净利润 433,994,145.52元，根据《公司章程》和有关规定，按10%提取盈余公积33,676,463.43元，加上合 并报表年初未分配利润3,238,794,150.63元，扣除年度内 ...

Financial Performance - The company's operating revenue for 2025 was CNY 6,194,555,686.05, representing a 4.24% increase compared to CNY 5,942,534,449.13 in 2024[15] - The net profit attributable to shareholders for 2025 was CNY 233,565,964.81, a 32.02% increase from CNY 176,914,017.08 in 2024[15] - The net profit after deducting non-recurring gains and losses was CNY 187,317,668.24, which is a 53.25% increase compared to CNY 122,230,989.62 in 2024[15] - The basic earnings per share for 2025 was CNY 0.6790, up 32.02% from CNY 0.5143 in 2024[15] - The gross profit margin for packaging oil decreased to 11.82% in 2025 from 13.51% in 2024, reflecting a decline of 1.69%[31] - The sales revenue from packaged oil was approximately ¥3.79 billion in 2025, up 6.21% from ¥3.57 billion in 2024[32] - The company reported a net profit growth due to cost reduction and efficiency improvements despite raw material price fluctuations[31] - The sales of bulk oil increased significantly by 55.42% year-on-year, reaching approximately ¥993.6 million in 2025[31] - The revenue from the food processing sector was ¥6,155,626,416.8, accounting for 99.37% of total revenue, with a year-on-year growth of 4.21%[44] - The gross profit margin for the food processing sector was 8.27%, a decrease of 1.23% compared to the previous year[46] Cash Flow and Assets - The net cash flow from operating activities decreased by 68.59% to CNY 993,348,622.88 from CNY 3,162,741,954.31 in 2024[15] - Total assets at the end of 2025 were CNY 4,166,495,082.34, a 3.23% increase from CNY 4,036,196,359.98 at the end of 2024[15] - The net assets attributable to shareholders increased by 5.90% to CNY 2,245,570,744.45 at the end of 2025 from CNY 2,120,504,704.35 at the end of 2024[15] - Cash and cash equivalents increased significantly by 559.38% to CNY 257,847,408.30 from CNY 39,104,437.06 in the previous year[56] - The company's total assets showed a significant increase in cash and cash equivalents, which accounted for 13.35% of total assets at the end of 2025, up from 7.15% at the beginning of the year[60] Dividends and Profit Distribution - The company plans to distribute a cash dividend of CNY 1.20 per 10 shares, based on a total of 343,968,305 shares[3] - The company plans to distribute a cash dividend of 1.28 RMB per 10 shares, totaling 44,027,943.03 RMB, based on a total share capital of 343,968,305 shares for the 2024 profit distribution[123] - For the 2025 mid-year profit distribution, the company will distribute a cash dividend of 1.76 RMB per 10 shares, amounting to 60,538,421.68 RMB, also based on the same total share capital[124] - The total distributable profit for the period is 82,572,433.60 CNY, with the cash dividend accounting for 100% of the profit distribution[126] - The company has not proposed any stock dividends or capital reserve transfers for this profit distribution plan[127] Market Position and Strategy - The company maintains a leading position in the canola oil market, recognized as a key brand in the edible oil sector[26] - The company aims to expand its market coverage and deepen its product offerings in response to evolving consumer preferences for high-quality and functional oils[39] - The company operates under a dual sales model, primarily through distributors and direct sales, with a focus on enhancing direct sales efforts[31] - The company has implemented a digital management transformation to enhance operational efficiency and management effectiveness[39] - The company faces risks from raw material price fluctuations, which can significantly impact profitability despite using financial derivatives for hedging[79] Research and Development - The company's R&D investment for 2025 was CNY 4,967,717.26, a decrease of 22.48% from CNY 6,407,973.20 in 2024[54] - R&D investment as a percentage of operating revenue fell to 0.08% in 2025 from 0.11% in 2024, a decline of 0.03%[54] - The number of R&D personnel remained stable at 26, with a slight increase in the proportion of undergraduate staff to 38.46%[54] Governance and Management - The company has established a market value management system to enhance governance and protect the interests of stakeholders[87] - The company has established specialized committees including the Strategic Development Committee, Audit Committee, Nomination Committee, and Compensation and Assessment Committee to provide professional advice for board decisions[94] - The company emphasizes information disclosure and investor relations management, ensuring timely and accurate information is shared through designated media[94] - The company has a complete and independent business and operational capability, with no reliance on controlling shareholders or other related parties[96] - The company has established a comprehensive internal control system to enhance decision-making and independence[109] Employee and Labor Relations - The total number of employees at the end of the reporting period was 1,134, with 466 in the parent company and 668 in major subsidiaries[119] - The company has established a training system to enhance employee skills and promote career development, including various training programs[121] - The company prioritizes employee rights protection, enhancing welfare systems and providing a comfortable working environment to foster employee growth and cohesion[136] Legal and Compliance - There were no significant lawsuits or arbitration matters during the reporting period, with a total of 8 cases where the company was a defendant, none of which were deemed significant[150] - The company has not faced any penalties or rectification issues during the reporting period[152] - The company actively complied with legal regulations and made prudent decisions on significant matters[115] Future Outlook - The outlook for 2026 indicates a growing demand for healthy and safe cooking oils, with a focus on product innovation and consumer experience[76] - The company anticipates that the edible oil industry will undergo significant changes due to evolving consumer preferences and macroeconomic factors[76] - The company aims to enhance supply chain resilience to better respond to market fluctuations and uncertainties[76]